☆ 4.5 Article

Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms

JAMA NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease

Shorena Janelidze et al.

Summary: Plasma phospho-tau species, especially p-tau217, show promise as blood-based biomarkers for Alzheimer's disease. This study compared the performance of different assays for p-tau181, p-tau217, and p-tau231 in detecting abnormal A beta status and predicting progression to Alzheimer's dementia. The mass spectrometry-based p-tau217 (p-tau217(WashU)) demonstrated the best performance, while several immunoassays, including p-tau217(Lilly), p-tau217(Janss), p-tau181(ADx), and p-tau181(WashU), showed high accuracy in both outcomes.

BRAIN (2023)

Add to Collection

Article Medical Laboratory Technology

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Johan Gobom et al.

Summary: The study evaluated the LUMIPULSE G assays for core cerebrospinal fluid biomarkers and established cutpoints for Alzheimer's disease diagnosis. Results showed strong correlation and reliable analytical performance of the LUMIPULSE G assays.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2022)

Add to Collection

Review Clinical Neurology

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Rik Ossenkoppele et al.

Summary: Innovative second-generation tau-PET tracers have enabled the early detection of tau pathology in the medial temporal lobe. Novel phosphorylated tau (p-tau) assays in the cerebrospinal fluid (CSF) better reflect tau tangle load. Furthermore, blood-based biomarkers for tau pathology show promise in predicting disease progression and differentiating Alzheimer's disease from other types of dementia.

LANCET NEUROLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Rik Ossenkoppele et al.

Summary: Abnormal amyloid and tau PET in cognitively unimpaired individuals is strongly associated with short-term cognitive decline and subsequent development of dementia.

NATURE MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18-F MK-6240 Positron Emission Tomography

John P. Seibyl et al.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Relationship Between Tau and Cognition in the Evolution of Alzheimer's Disease: New Insights from Tau PET

Jeremy A. Tanner et al.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison

Daniele Altomare et al.

Summary: The study found that both amyloid-PET and tau-PET have a significant impact on diagnosis and diagnostic confidence when used as the first exam, with a stronger impact observed for a negative amyloid-PET result. Adding either of the two as a second exam further improved diagnostic confidence.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Article Clinical Neurology

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Shorena Janelidze et al.

Summary: This study highlights the potential of plasma P-tau217 as an early biomarker for Alzheimer's disease, showing elevated levels before tau-PET detected insoluble tau aggregates. Modeling suggests that changes in plasma and CSF P-tau217 precede tau-PET signals, indicating its usefulness in detecting early AD brain pathology.

JAMA NEUROLOGY (2021)

Add to Collection

Review Chemistry, Medicinal

Tauvid (TM): The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease

Caitlin V. M. L. Jie et al.

Summary: Tauvid, approved by the FDA in 2020 for PET imaging in AD patients, is a significant advancement in the field of AD research. This review summarizes the production, quality control, clinical application, pharmacology, and limitations of Tauvid, while also providing an overview of second-generation tau PET tracers.

PHARMACEUTICALS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Biomarkers for neurodegenerative diseases

Oskar Hansson

Summary: Biomarkers for neurodegenerative diseases play a crucial role in improving diagnostic workup and therapy monitoring, with emerging blood-based markers and discussions on their implementation in clinical practice and trials.

NATURE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging

Rik Ossenkoppele et al.

Summary: This study demonstrates the prognostic accuracy of tau PET in predicting cognitive changes, which is superior to MRI and amyloid PET markers, supporting the prognostic process in early stages of Alzheimer's disease.

JAMA NEUROLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948

Ruben Smith et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)

Add to Collection

Article Clinical Neurology

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

Adam S. Fleisher et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

Antoine Leuzy et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

A beta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease

Niklas Mattsson-Carlgren et al.

SCIENCE ADVANCES (2020)

Add to Collection

Article Clinical Neurology

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

Tharick A. Pascoal et al.

BRAIN (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study

Michael J. Pontecorvo et al.

EJNMMI RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

Gil D. Rabinovici et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Article Clinical Neurology

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

Clifford R. Jack et al.

BRAIN (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Tau PET imaging in neurodegenerative tauopathies-still a challenge

Antoine Leuzy et al.

MOLECULAR PSYCHIATRY (2019)

Add to Collection

Article Clinical Neurology

Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology

Ruben Smith et al.

JAMA NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

Oskar Hansson et al.

ALZHEIMERS & DEMENTIA (2018)

Add to Collection

Article Medicine, General & Internal

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

Rik Ossenkoppele et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Clinical Neurology

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

Ruben Smith et al.

BRAIN (2016)

Add to Collection

Article Clinical Neurology

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

Victor L. Villemagne et al.

LANCET NEUROLOGY (2013)

Add to Collection

Article Psychiatry

Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

Peder Buchhave et al.

ARCHIVES OF GENERAL PSYCHIATRY (2012)

Add to Collection

Review Multidisciplinary Sciences

Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics

J Hardy et al.

SCIENCE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.